XML 80 R79.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details) | 3 Months Ended | 1 Months Ended | 3 Months Ended |
--- | --- | --- | --- | ---
Mar. 31, 2015 USD ($) | Mar. 31, 2014 USD ($) | Feb. 29, 2012 Samsung Biosimilar Agreement [Member] USD ($) | Feb. 29, 2012 Samsung Biosimilar Agreement [Member] KRW | Mar. 31, 2015 Samsung Biosimilar Agreement [Member] USD ($) | Mar. 31, 2015 Samsung Biosimilar Agreement [Member] KRW | Mar. 31, 2014 Samsung Biosimilar Agreement [Member] USD ($) | Dec. 31, 2013 Samsung Biosimilar Agreement [Member] USD ($) | Dec. 31, 2014 Samsung Biosimilar Agreement [Member] USD ($) | Dec. 31, 2014 Samsung Biosimilar Agreement [Member] KRW
Schedule of Equity Method Investments [Line Items] |  |  |  |  |  |  |  |  |  |
Contribution from Samsung to develop, manufacture and market biosimilar pharmaceuticals |  |  | $ 250,000,000 biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 280,500,000,000 biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |  |  |  |
Variable interest entity, qualitative or quantitative information, ownership percentage |  |  | 85.00%biib_JointVentureOwnerShipPercentageByThirdParty / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 85.00%biib_JointVentureOwnerShipPercentageByThirdParty / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |  |  |  |
Contribution from Biogen to develop, manufacture and market biosimilar pharmaceuticals |  |  | 45,000,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 49,500,000,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 12,400,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 13,600,000,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  | 8,600,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 9,100,000,000 us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember
Percentage of stake in entity minimum |  |  | 15.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 15.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 10.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 10.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |  |
Additional contribution made to Samsung Bioepis |  |  |  |  | 5,700,000 us-gaap_PaymentsToAcquireEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 6,300,000,000 us-gaap_PaymentsToAcquireEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |  |
Percentage of stake in entity maximum |  |  | 49.90%biib_EquityMethodInvestmentOwnershipPercentageMaximum / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember | 49.90%biib_EquityMethodInvestmentOwnershipPercentageMaximum / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |  |  |  |
Recognized loss | (834,000)us-gaap_IncomeLossFromEquityMethodInvestments | (7,605,000)us-gaap_IncomeLossFromEquityMethodInvestments |  |  | (800,000)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  | (7,600,000)us-gaap_IncomeLossFromEquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |
Research and development | 460,549,000 us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | 528,884,000 us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost |  |  |  |  |  | 36,000,000 us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |
Additional milestone payment |  |  |  |  |  |  |  | 75,000,000 biib_AdditionalMilestonePayment / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |
Expected profit share with Samsung Bioepis |  |  |  |  |  |  |  | 50.00%biib_EquityMethodInvestmentsExpectedProfitShare / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |
Revenue related to technical development and technology transfer services | $ 52,030,000 us-gaap_OtherSalesRevenueNet | $ 90,101,000 us-gaap_OtherSalesRevenueNet |  |  | $ 18,900,000 us-gaap_OtherSalesRevenueNet / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  | $ 24,100,000 us-gaap_OtherSalesRevenueNet / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = biib_SamsungBiosimilarAgreementMember |  |  |

X
- Definition Additional milestone payment. + References No definition available. + Details
Name: | biib_AdditionalMilestonePayment
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Equity method investment ownership percentage maximum. + References No definition available. + Details
Name: | biib_EquityMethodInvestmentOwnershipPercentageMaximum
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Method Investments, Expected Profit Share + References No definition available. + Details
Name: | biib_EquityMethodInvestmentsExpectedProfitShare
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investments by third party in joint venture as per agreement + References No definition available. + Details
Name: | biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Joint venture owner ship percentage by third party. + References No definition available. + Details
Name: | biib_JointVentureOwnerShipPercentageByThirdParty
Namespace Prefix: | biib_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 + Details
Name: | us-gaap_EquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 9 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=35755396&loc=d3e33749-111570 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.12) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 11 -Article 7 + Details
Name: | us-gaap_IncomeLossFromEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a),(d)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_OtherSalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Research and Development -URI http://asc.fasb.org/extlink&oid=6523717 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration